Mar 30, 2026 |
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated MilestonesMar 16, 2026 |
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)Feb 17, 2026 |
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic AtrophyJan 16, 2026 |
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)Jan 08, 2026 |
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome